A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). (2015)

First Author: Fervenza FC
Attributed to:  Understanding the autoimmune mechanism in idiopathic membranous nephropathy (IMN) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1159/000430849

PubMed Identifier: 26087670

Publication URI: http://europepmc.org/abstract/MED/26087670

Type: Journal Article/Review

Volume: 130

Parent Publication: Nephron

Issue: 3

ISSN: 1660-8151